Cytek Biosciences to Participate in Upcoming Investor Conferences
Cytek Biosciences (CTKB) will participate in the UBS Global Healthcare Conference and Stephens Annual Investment Conference in November 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cytek Biosciences (CTKB) will participate in the UBS Global Healthcare Conference and Stephens Annual Investment Conference in November 2026.
CFO William McCombe and Head of Investor Relations Mark Meehan will hold investor meetings in Palm Beach Gardens on November 9. CEO Wenbin Jiang and McCombe will join a fireside chat in Nashville on November 17 at 6:00 a.m. Pacific / 9:00 a.m. Eastern. A live and archived Stephens webcast will be available on the company’s investor website.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FREMONT, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences:
- UBS Global Healthcare Conference in Palm Beach Gardens, FL
CFO William McCombe and Head of Investor Relations Mark Meehan will be participating in investor meetings on Monday, November 9, 2026
- Stephens Annual Investment Conference in Nashville, TN
CEO Wenbin Jiang and CFO William McCombe will be participating in a fireside chat on Tuesday, November 17, 2026, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time
Interested parties may access the live and archived webcast for the Stephens event referenced above on the “Investors” section of the company website at: investors.cytekbio.com.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS, Cytek Aurora™ Evo, and Cytek Borealis™ systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.
Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Cytek Borealis, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X account as channels of distribution for information about the company, its products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Certain information disseminated through these channels may be material to investors, and Cytek may use these channels to disseminate such information in accordance with Regulation FD and other applicable disclosure requirements. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
Investor Contact:
Mark Meehan
Cytek Biosciences
mmeehan@cytekbio.com
